sha

 **1. Study Identification**

* **Unique Protocol Identification Number** **\***  
  NA

**Brief Title** **\***  
A randomized trial of internet-based decision aid for perimenopausal and menopausal women

**Acronym** **[\*]**  
NA

**Official Title** **\*§**  
Definition: The title of the clinical study, corresponding to the title of the protocol.

**Study Type** **\***  
Definition: The nature of the investigation or investigational use for which clinical study information is being submitted. Select one.

* + Interventional (clinical trial): Participants are assigned prospectively to an intervention or interventions according to a protocol to evaluate the effect of the intervention(s) on biomedical or other health related outcomes.

 **2. Study Status**

* **Record Verification Date** **\***  
  Date of entry to the website

**Overall Recruitment Status** **\***

* + Recruiting: Participants are currently being recruited, whether or not any participants have yet been enrolled

**Why Study Stopped** **\*§**  
Limit: 250 characters.  
Definition: NA – the study is ongoing).

**Study Start Date** **\*§**  
12 Jan 2022

**Primary Completion Date** **\* 2/15/2022**

15 Feb 2022

**Study Completion Date** **\*§**

15 Feb 2022

 **3. Sponsor/Collaborators**

**Responsible Party, by Official Title** **\***  
Definition: An indication of whether the responsible party is the sponsor, the sponsor-investigator, or a principal investigator designated by the sponsor to be the responsible party. Select one.

* Principal Investigator: The individual designated as responsible party by the sponsor (see Note)

**Investigator Information**  
If the Responsible Party, by Official Title is either "Principal Investigator" or "Sponsor-Investigator," the following is required:

**Investigator Name**: Andrea Z. LaCroix

* **Investigator Official Title**: Professor and Chief of Epidemiology, Family Medicine and Public Health
* **Investigator Affiliation**: University of California San Diego

**Investigator Name**: Katherine A. Guthrie

* **Investigator Official Title**: Professor, Cancer Prevention Program Public Health Sciences Division, Fred Hutch
* **Investigator Affiliation**: Fred Hutchinson Cancer Research Center

**Investigator Name**: Susan D. Reed

* **Investigator Official Title**: Professor, Obstetrics and Gynecology
* **­Investigator Affiliation** University of Washington

**Name of the Sponsor** **\***  
National Institute of Health - National Institute on Aging

**Collaborators**  
Definition: Other organizations (if any) providing support. Support may include funding, design, implementation, data analysis or reporting. The responsible party is responsible for confirming all collaborators before listing them.  
Limit: 160 characters.

 **4. Oversight**

**Human Subjects Review** **\***  
Definition: Studies must have approval (or be exempt, as appropriate) from a Human Subjects Protection Review Board prior to the enrollment of the first participant to be eligible for registration. A study may be submitted for registration prior to approval by the review board so long as the study is not yet recruiting participants.

**Human Subjects Protection Review Board Status** **\***

* + - Submitted, approved: Review board approval has been requested and obtained
    - **Board Approval Number** **[\*]**  
      140604
    - **Board Name** **[\*]**  
      [Office of IRB Administration](https://irb2.ucsd.edu/) [UC San Diego](http://www.ucsd.edu)
    - **Board Affiliation** **[\*]**  
      [Office of IRB Administration](https://irb2.ucsd.edu/) [UC San Diego](http://www.ucsd.edu)
    - **Board Contact** **[\*]**
      * **Phone** (or Email required): **858-246-4777**
      * **Extension**:NA
      * **Email** (or Phone required): [**IRB@ucsd.edu**](mailto:IRB@ucsd.edu)
      * **Address**: UC San Diego 9500 Gilman Dr. La Jolla, CA 92093
* **Data Monitoring Committee NONE**

 **5. Study Description**

* **Brief Summary** **\***  
  Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public.  
  Limit: 5000 characters.

 **6. Conditions and Keywords**

**Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study** **perimenopause, menopause**

MeSH Heading

**Premenopause**

Tree Number(s)

G08.686.157.500.812

G08.686.841.249.500.812

Unique ID

D017697

RDF Unique Identifier

[http://id.nlm.nih.gov/mesh/D017697](https://id.nlm.nih.gov/mesh/D017697.html)

Scope Note

The period before [MENOPAUSE](https://meshb.nlm.nih.gov/record/ui?ui=D008593). In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.

Entry Term(s)

Pre-Menopause

Pre-menopausal Period

Premenopausal Period

MeSH Heading

**Menopause**

Tree Number(s)

G08.686.157.500

G08.686.841.249.500

Unique ID

D008593

RDF Unique Identifier

[http://id.nlm.nih.gov/mesh/D008593](https://id.nlm.nih.gov/mesh/D008593.html)

Annotation

[PERIMENOPAUSE](https://meshb.nlm.nih.gov/record/ui?ui=D047648); [PREMENOPAUSE](https://meshb.nlm.nih.gov/record/ui?ui=D017697); and [POSTMENOPAUSE](https://meshb.nlm.nih.gov/record/ui?ui=D017698) are available

Scope Note

The last menstrual period. Permanent cessation of menses ([MENSTRUATION](https://meshb.nlm.nih.gov/record/ui?ui=D008598)) is usually defined after 6 to 12 months of [AMENORRHEA](https://meshb.nlm.nih.gov/record/ui?ui=D000568) in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Entry Term(s)

Change of Life, Female

MeSH Heading

**Postmenopause**

Tree Number(s)

G08.686.157.500.625

G08.686.841.249.500.625

Unique ID

D017698

RDF Unique Identifier

[http://id.nlm.nih.gov/mesh/D017698](https://id.nlm.nih.gov/mesh/D017698.html)

Scope Note

The physiological period following the [MENOPAUSE](https://meshb.nlm.nih.gov/record/ui?ui=D008593), the permanent cessation of the menstrual life.

Entry Term(s)

Post-Menopause

Post-menopausal Period

Postmenopausal Period

MeSH Heading

Internet-Based Intervention

Tree Number(s)

L01.224.230.110.500.688

Unique ID

D000079382

RDF Unique Identifier

[http://id.nlm.nih.gov/mesh/D000079382](https://id.nlm.nih.gov/mesh/D000079382.html)

Scope Note

Use of the [INTERNET](https://meshb.nlm.nih.gov/record/ui?ui=D020407) to facilitate the dissemination of health-related information and to connect patients to support.

Entry Term(s)

Internet Intervention

Online Intervention

Web-based Intervention

MeSH Heading

**Decision Making, Computer-Assisted**

Tree Number(s)

L01.313.500.750.100

Unique ID

D003658

RDF Unique Identifier

[http://id.nlm.nih.gov/mesh/D003658](https://id.nlm.nih.gov/mesh/D003658.html)

Scope Note

Use of an interactive computer system designed to assist the physician or other health professional in choosing between certain relationships or variables for the purpose of making a diagnostic or therapeutic decision.

Entry Term(s)

Computer-Assisted Decision Making

Medical Decision Making, Computer-Assisted

**7. Study Design**

* **Interventional Study Design** **\*** (*For interventional studies only*)  
  Definition: A description of the manner in which the clinical trial will be conducted, including the following information:
  + **Primary Purpose** **\*§**  
    Definition: The main objective of the intervention(s) being evaluated by the clinical trial. Select one.
    - Health Services Research: One or more interventions for evaluating the delivery, processes, management, organization, or financing of healthcare
    - If description is asked: To assess the effectiveness of an newly developed, scientifically based website for women about perimenopause and menopause, compared to other websites.
  + **Study Phase** **\***  
    Definition: For a clinical trial of a drug product (including a biological product), the numerical phase of such clinical trial, consistent with terminology in 21 CFR 312.21 and in 21 CFR 312.85 for phase 4 studies. Select only one.
    - N/A: Trials without phases (for example, studies of devices or behavioral interventions).
  + **Interventional Study Model** **\*§**  
    Definition: The strategy for assigning interventions to participants.
    - Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study
    - **Model Description**  
      Definition: Provide details about the Interventional Study Model.  
      Limit: 1000 characters.
  + **Number of Arms** **\*2§**  
    Definition: The number of arms in the clinical trial. For a trial with multiple periods or phases that have different numbers of arms, the maximum number of arms during all periods or phases.

Note: "Arm" means a pre-specified group or subgroup of participant(s) in a clinical trial assigned to receive specific intervention(s) (or no intervention) according to a protocol.

* + **Masking** **\*§**  
    Definition: The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants. Select all that apply.
    - Roles, if Masking:
      * Participant

**Masking Description**  
Definition: Provide information about other parties who may be masked in the clinical trial, if any.  
Participants were randomly assigned to either the MyMenoplan website or the following:

North American Menopause Society: <https://www.menopause.org/for-women>  
  
National Institute on Aging: <https://www.nia.nih.gov/health/topics/menopause>  
  
The Office on Women’s Health-Menopause: <https://www.womenshealth.gov/menopause>

* + **Allocation** **\*§**  
    Definition: The method by which participants are assigned to arms in a clinical trial.
    - Randomized: Participants are assigned to intervention groups by chance, they were assigned by a random number generator by birth month
  + **Enrollment** **\*estimated 300§**
* **Observational Study Design** (*For observational studies only*)
  + **Observational Study Model** **\*NA**
  + **Time Perspective** **\***  
    Definition: Temporal relationship of observation period to time of
    - Cross-sectional: Observations or measurements made at a single point in time, usually at subject enrollment

**Enrollment** **\*n=300**  
**Target Follow-Up Duration** **\*NA**

* + **Defin**ition: For Patient Registries, the anticipated time period over which each participant is to be followed. Provide a number and select a Unit of Time (years, months, weeks, days).
  + **Number of Groups/Cohorts** **\*2**
  + Definition: Number of study groups/cohorts. Enter "1" for a single-group study. Many observational studies have one group/cohort; case control studies typically have two.

 **8. Arms, Groups, and Interventions**

* **Arm Information \***(*For interventional studies only*)  
  Definition: A description of each arm of the clinical trial that indicates its role in the clinical trial; provides an informative title; and, if necessary, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.  
    
  Note: "Arm" means a pre-specified group or subgroup of participant(s) in a clinical trial assigned to receive specific intervention(s) (or no intervention) according to a protocol.
  + **Arm Title** **\* INTERVENTION**
  + Definition: The short name used to identify the arm.  
    Limit: 100 characters.
  + **Arm Type**   
    Definition: The role of each arm in the clinical trial.
    - Experimental
* **Arm Description** **[\*]**  
  Participants are asked to spent at least 20 minutes on the website (MyMenoplan) assigned to them.
  + **Arm Title** **\*CONTROL**  
    Definition: The short name used to identify the arm.  
    Limit: 100 characters.
  + **Arm Type**    
    Definition: The role of each arm in the clinical trial.
    - Active Comparator
  + **Arm Description**
  + Participants are asked to spent at least 20 minutes on at least one of the following websites:
  + North American Menopause Society: <https://www.menopause.org/for-women>  
      
    National Institute on Aging: <https://www.nia.nih.gov/health/topics/menopause>  
      
    The Office on Women’s Health-Menopause: <https://www.womenshealth.gov/menopause>

**Group/Cohort Information** (*For observational studies only*)  
Definition: Specify the predefined participant groups (cohorts) to be studied, corresponding to Number of Groups specified under Study Design (for single-group studies, the following data elements are optional). Do not use this section to specify strata (Detailed Description can be used for that purpose, if desired).

* + **Group/Cohort Label** **\*I/C**  
    Definition: The short name used to identify the group.  
    Limit: 100 characters.
  + **Group/Cohort Description** **[\*]**  
    Definition: Explanation of the nature of the study group (for example, those with a condition and those without a condition; those with an exposure and those without an exposure).  
    Limit: 999 characters.

Note: The overall study population should be described under Eligibility.

**Interventions** **\***  
Definition: Specify the intervention(s) associated with each arm or group; at least one intervention must be specified for interventional studies. For observational studies, specify the intervention(s)/exposure(s) of interest, if any. If the same intervention is associated with more than one arm or group, provide the information once and use the Arm or Group/Intervention Cross-Reference to associate it with more than one arm or group.

* + **Intervention Type** **\***  
    Definition: For each intervention studied in the clinical study, the general type of intervention. Select one.
    - Behavioral: For example, psychotherapy, lifestyle counseling
  + **Intervention Name(s)** **\***  
    MyMenoplan
    - **Other Intervention Name(s)** **[\*]**  
      NA
  + **Intervention Description** **\*§**  
    The goal of the intervention is to evaluate the utility of an internet-based decision tool for menopause treatment and management
* **Arm or Group/Interventional Cross-Reference** **\***  
  Definition: If multiple Arms or Groups have been specified, indicate which Interventions (or exposures) are in each Arm or Group of the study, using the Cross-Reference check boxes.

 **9. Outcome Measures**

* **Primary Outcome Measure Information** **\***  
  Definition: A description of each primary outcome measure (or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).

Note: "Primary outcome measure" means the outcome measure(s) of greatest importance specified in the protocol, usually the one(s) used in the power calculation. Most clinical studies have one primary outcome measure, but a clinical study may have more than one.

For each primary outcome measure, include the following information:

***Title****:****\*****Name of the specific primary outcome measure  
Limit: 254 characters.*

***Description****:****[\*]****Description of the metric used to characterize the specific primary outcome measure, if not included in the primary outcome measure title.  
Limit: 999 characters.*

* + **Title**: Perceived Quality of Information
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Readability
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Self Efficacy
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Clarity of Values (Clear about what to do next?)
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Credibility
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
* **Secondary Outcome Measure Information** **[\*]**  
  Definition: A description of each secondary outcome measure (or for observational studies, specific secondary measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment).

Note: "Secondary outcome measure" means an outcome measure that is of lesser importance than a primary outcome measure, but is part of a pre-specified analysis plan for evaluating the effects of the intervention or interventions under investigation in a clinical study and is not specified as an exploratory or other measure. A clinical study may have more than one secondary outcome measure.

For each secondary outcome measure, include the following information:

* + **Title**: Attractiveness of Website
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Being Informed
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Intention of Future Use
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Knowledge Gain
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Health Literacy Skills
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Relevance to user
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Intention to talk to doctor
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title**: Reduce Uncertainty
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title: I**ntent to Change
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**
  + **Title:** Progress in decision making
  + **Description**:
  + **Time Frame**: **\*immediate – the questionnaire is completed immediately after subjects visit their assigned website(s)**

 **10. Eligibility**

* **Sex/Gender** **\*female**  
  Definition: The sex and, **if applicable, gender** of the participants eligible to participate in the clinical study.
  + **Sex** **\*female**  
    Definition: The sex of the participants eligible to participate in the clinical study. Select one.Note: "Sex" means a person's classification as male or female based on biological distinctions.
    - **Gender Based** **[\*]**  
      Definition: If applicable, indicate whether participant eligibility is based on gender. Select one.

Note: "Gender" means a person's self-representation of gender identity.

* + - * **Yes: Eligibility is based on gender**
      * **Gender Eligibility Description**  
        a non-binary person is someone who does not identify as exclusively a man or a woman.
      * A transgender male is a man who was assigned female at birth
* **Age Limits** **\***  
  Definition: The minimum and maximum age of potential participants eligible for the clinical study, provided in relevant units of time.
  + **Minimum Age** **\***40
  + **Unit of Time** **\***  
    Select one.
    - Years
  + **Maximum Age** **\***60
  + **Unit of Time** **\***  
    Select one.
    - Years
* **Accepts Healthy Volunteers** **\*§** (*Optional for Observational Studies*)  
  Yes
* **Eligibility Criteria** **\***  
  Definition: A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers "Inclusion Criteria" and "Exclusion Criteria".  
  Limit: 20,000 characters.

 **11. Contacts, Locations, and Investigator Information**

* **Central Contact Person** **\*** (*or Facility Contact required*)  
  Definition: The name or title, toll-free telephone number and email address of a person to whom questions concerning enrollment at any location of the study can be addressed. Include the following information:
  + **First Name** 
    - Hui Xin
  + **Middle Initial**
  + **Last Name or Official Title** **\***
    - Ng
  + **Degree**
  + **Phone**: **8452489039**
  + **Ext**: phone extension, if needed
  + **Email**: **hxng@ucsd.edu**
* **Overall Study Officials**  
  Definition: Person(s) responsible for the overall scientific leadership of the protocol, including study principal investigator. Include the following information:
  + **First Name** Andrea
  + **Middle Initial** Z.
  + **Last Name** LaCroix
  + **Degree** PhD, Epidemiology
  + **Organizational Affiliation** University of California San Diego
  + **Official's Role**: Position or function of the official. Select one
    - Study Principal Investigator
  + **First Name** Katherine
  + **Middle Initial** M.
  + **Last Name** Newton
  + **Degree** PhD in Epidemiology
  + **Organizational Affiliation** Kaiser Permanente
  + **Official's Role**:
    - Study Co- Principal Investigator
  + **First Name** Leslie
  + **Middle Initial**
  + **Last Name** Snyder
  + **Degree** PhD, Communications
  + **Organizational Affiliation** University of Connecticut
  + **Official's Role**:
    - Study Co-Principal Investigator
* **Facility Information** **\*NA this is a web-based study**  
  **Individual Site Status** **\***  
  NA

 **12. IPD Sharing Statement**

* **Plan to Share IPD**  
  Definition: Indicate whether there is a plan to make individual participant data (IPD) collected in this study, including data dictionaries, available to other researchers (typically after the end of the study). Select one.
  + Yes: There is a plan to make IPD and related data dictionaries available

**IPD Sharing Plan Description**  
Definition: If Plan to Share IPD is "Yes," briefly describe what specific individual participant data sets are to be shared

If Plan to Share IPD is "Yes," provide the following information.

* + **IPD Sharing Supporting Information Type**  
    Definition: The type(s) of supporting information that will be shared, in addition to the individual participant data set and data dictionaries for the IPD itself. Select all that apply.
    - Clinical Study Report (CSR)

**IPD Sharing Time Frame**  
Definition: A description of when the IPD and any additional supporting information will become available and for how long, including the start and end dates or period of availability. This may be provided as an absolute date (for example, starting in January 2025) or as a date relative to the time when summary data are published or otherwise made available (for example, starting 6 months after publication).  
Limit: 1000 characters.

* + **IPD Sharing Access Criteria**  
    Definition: Describe by what access criteria IPD and any additional supporting information will be shared, including with whom, for what types of analyses, and by what mechanism. Information about who will review requests and criteria for reviewing requests may also be provided.  
    Limit: 1000 characters.
  + De identified dataset underlying primary trial report will be made available at time of publication through journal or upon request
  + **IPD Sharing URL**  
    NA

 **13. References**

* **Citations**  
  Definition: Citations to publications related to the protocol: background and/or results. Provide either the PubMed Unique Identifier (PMID) of an article or enter the full bibliographic citation.
  + **PubMed Identifier**, **Citation**  
    De identified dataset underlying primary trial report will be made available at time of publication through journal or upon req

[Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA 2011;305(3):267-274. [PMCID: PMC3129746]](http://mymenoplan.org/wp-content/uploads/2020/12/ms01.pdf)

[Joffe H, Guthrie KA, Larson J, Cohen LS, Carpenter JS, LaCroix AZ, Freeman EW. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor Escitalopram: results from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network. Menopause 2013;20(3):261-268. [PMCID: PMC3561495]](http://mymenoplan.org/wp-content/uploads/2020/12/ms02.pdf)

[Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, Ensrud KE, Freeman EW, Joffe H, Sternfeld B, Reed SD, Sherman S, Sammel MD, Kroenke K, Larson JC, LaCroix AZ. Methods for the design of vasomotor symptom trials: the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network. Menopause 2014;21(1):45-58. [PMCID: PMC3796184]](http://mymenoplan.org/wp-content/uploads/2020/12/ms03.pdf)

[Carpenter JS, Newton KN, Sternfeld BS, Joffe H, Reed SD, Ensrud KE, Milata J. Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network. Menopause 2012;19(6):664-671. [PMCID: PMC3326209]](http://mymenoplan.org/wp-content/uploads/2020/12/ms05.pdf)

[Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, Ensrud KE, LaCroix AZ. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril 2012;97(6):1399-1404. [PMCID: PMC3367120]](http://mymenoplan.org/wp-content/uploads/2020/12/ms06.pdf)

[Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, LaCroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012;19(8):848-855. [PMCID: PMC3382013]](http://mymenoplan.org/wp-content/uploads/2020/12/ms07.pdf)

[Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012;119(3):527-538. [PMCID: PMC3345186]](http://mymenoplan.org/wp-content/uploads/2020/12/ms08.pdf)

[Otte JL, Rand KC, Landis C, Paudel M, Newton KM, Woods N, Carpenter JS. Confirmatory factor analysis of the Pittsburgh sleep quality index in women with hot flashes. Menopause 2015;22(11):1190-1196. [PMCID: PMC4624473]](http://mymenoplan.org/wp-content/uploads/2020/12/ms09.pdf)

[LaCroix AZ, Freeman EW, Larson J, Carpenter JS, Joffe H, Reed SD, Newton KM, Seguin RA, Sternfeld B, Cohen L, Ensrud KE. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012;73(4):361-368. [PMCID: PMC3645479]](http://mymenoplan.org/wp-content/uploads/2020/12/ms10.pdf)

[Sternfeld BS, Guthrie KA, Ensrud KE, LaCroix AZ, Larson JC, Dunn AL, Anderson GL, Sequin RA, Carpenter JS, Newton KM, Reed SD, Freeman EW, Cohen LS, Joffe H, Roberts M, Caan BJ. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014;21(4):330-338. [PMCID: PMC3858421]](http://mymenoplan.org/wp-content/uploads/2020/12/ms11.pdf)

[Cohen LS, Joffe H, Guthrie KA, Ensrud KE, Freeman MP, Carpenter JS, Learman LA, Newton KM, Reed SD, Manson JE, Sternfeld B, Caan BJ, Freeman EW, LaCroix AZ, Tinker LF, Booth-LaForce C, Larson JC, Anderson GL. Efficacy of Omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause 2014;21(4):347-354. [PMCID: PMC4072122]](http://mymenoplan.org/wp-content/uploads/2020/12/ms12.pdf)

[Newton KM, Reed SD, Guthrie KA, Sherman KJ, Booth-LaForce C, Caan B, Sternfeld B, Carpenter JS, Learman LA, Freeman EW, Cohen LS, Joffe H, Anderson GL, Larson JC, Hunt JR, Ensrud KE, LaCroix AZ. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause 2014;21(4):339-346. [PMCID: PMC3871975]](http://mymenoplan.org/wp-content/uploads/2020/12/ms13.pdf)

[Sternfeld B, LaCroix A, Caan BJ, Dunn AL, Newton KM, Reed SD, Guthrie KA, Booth-LaForce C, Sherman KJ, Cohen L, Freeman MP, Carpenter JS, Hunt JR, Roberts M, Ensrud KE. Design and methods of a multi-site, multi-behavioral treatment trial for menopausal symptoms: the MsFLASH experience. Contemp Clin Trials 2013;35:25–34. [PMCID: PMC3670607]](http://mymenoplan.org/wp-content/uploads/2020/12/ms14.pdf)

[Reed SD, Guthrie KA, Newton KM, Anderson GL, Booth-LaForce C, Caan B, Carpenter JS, Cohen LS, Dunn AL, Ensrud KE, Freeman EW, Hunt JR, Joffe H, Larson JC, Learman LA, Rothenberg R, Seguin RA, Sherman KJ, Sternfeld BS, LaCroix AZ. Menopausal quality of life: RCT of yoga, exercise, and Omega-3 supplements. Am J Obstet Gynecol 2014;210(3):244.e1-244.e11. [PMCID: PMC3976276]](http://mymenoplan.org/wp-content/uploads/2020/12/ms15.pdf)

[Carpenter JS, Woods NF, Otte JL, Guthrie KA, Hohensee C, Newton KM, Joffe H, Cohen L, Sternfeld BS, Lau RJ, Reed SD, LaCroix AZ. MsFLASH participants’ priorities for alleviating menopausal symptoms. Climacteric 2015;18(6):1-8. [PMCID: PMC4732703]](http://mymenoplan.org/wp-content/uploads/2020/12/ms17.pdf)

[Carpenter JS, Reed SD, Guthrie KA, Larson JC, Newton KM, Lau RJ, Learman LA, Shifren JL. Using an FSDS-R item to screen for sexually related distress: a MsFLASH analysis. Sex Med 2015;3(1):7-13. [PMCID: PMC4380908]](http://mymenoplan.org/wp-content/uploads/2020/12/ms18.pdf)

[Carpenter JS, Jones SMW, Studts CR, Heiman JR, Shifren JL, Reed SD, Newton KM, Guthrie KA, Larson JC, Cohen LS, Freeman EW, Lau RJ, Learman LA. Female Sexual Function Index Short Version: a MsFLASH response analysis. Arch Sex Behav 2016;45(8):1897-1905. [PMCID: PMC5053877]](http://mymenoplan.org/wp-content/uploads/2020/12/ms19.pdf)

[Freeman EW, Ensrud K, Larson J, Guthrie KA, Carpenter J, Joffe H, Newton K, Sternfeld B, LaCroix AZ. Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors. Psychosom Med 2015;77(2):167-175. [PMCID: PMC4333078]](http://mymenoplan.org/wp-content/uploads/2020/12/ms20.pdf)

[Reed SD, Newton KM, Larson JC, Booth-LaForce C, Woods NF, Landis CA, Tolentino E, Carpenter JS, Freeman EW, Joffe H, Anawalt BD, Guthrie KA. Daily salivary cortisol patterns in midlife women with hot flashes. Clin Endocrinol (Oxf) 2016;84(5):672-679. [PMCID: PMC5106033]](http://mymenoplan.org/wp-content/uploads/2020/12/ms21.pdf)

[Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, Newton KM, Freeman EW, Anderson GL, Larson JC, Hunt JR, Shifren J, Rexrode KM, Caan B, Sternfeld B, Carpenter JS, Cohen LS. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174(7):1058-1066. [PMCID: PMC4179877]](http://mymenoplan.org/wp-content/uploads/2020/12/ms23.pdf)

[Otte JL, Bakoyannis G, Rand KL, Ensrud KE, Guthrie KA, Joffe H, McCurry SM, Newton KM, Carpenter JS. Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data. Menopause 2019; 26(8):850-855. PMC6663566](http://mymenoplan.org/wp-content/uploads/2020/12/ms27.pdf)

[Woods NF, Hohensee C, Carpenter JS, Cohen L, Ensrud K, Freeman EW, Guthrie KA, Joffe H, LaCroix AZ, Otte JL, Cochrane B. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016;23(2):158-165. [PMCID: PMC4731298]](http://mymenoplan.org/wp-content/uploads/2020/12/ms28.pdf)

[Mitchell CM, Srinivasan S, Zhan X, Wu MC, Reed SD, Guthrie KA, LaCroix AZ, Fiedler T, Munch M, Liu C, Hoffman NG, Blair IA, Newton K, Freeman E, Joffe H, Cohen L, Fredricks DN. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause 2017;24(10):1160-1166. [PMCID: PMC5607086]](http://mymenoplan.org/wp-content/uploads/2020/12/ms29.pdf)

[Guthrie KA, LaCroix AZ, Ensrud KE, Joffe H, Newton KM, Reed SD, Caan B, Carpenter JS, Cohen LS, Freeman EW, Larson JC, Manson JE, Rexrode K, Skaar TC, Sternfeld B, Anderson GL. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol 2015;126(2):413-422. [PMCID: PMC4526122]](http://mymenoplan.org/wp-content/uploads/2020/12/ms30.pdf)

[Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, Freeman EW, Larson JC, Manson JE, LaCroix AZ, Guthrie KA. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014;124(2 Pt 1):233-241. [PMCID: PMC4113909]](http://mymenoplan.org/wp-content/uploads/2020/12/ms31.pdf)

[Ensrud KE, Guthrie KA, Hohensee C, Caan B, Carpenter JS, Freeman EW, LaCroix AZ, Landis CA, Manson J, Newton KM, Otte J, Reed SD, Shifren JL, Sternfeld B, Woods NF, Joffe H. Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. Sleep 2015;38(1):97-108. [PMCID: PMC4262961]](http://mymenoplan.org/wp-content/uploads/2020/12/ms32.pdf)

[Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, Cohen LS, Freeman EW, Manson JE, Newton K, Reed S, Rexrode K, Shifren J, Sternfeld B, Ensrud K. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause 2015:22(6):607-615. [PMCID: PMC4610378]](http://mymenoplan.org/wp-content/uploads/2020/12/ms33.pdf)

[Diem SJ, Joffe H, Larson JC, Tsai JN, Guthrie KA, LaCroix AZ, Ensrud KE, Freeman EW, Leder BZ. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99(9):E1732-1737. [PMCID: PMC4154080]](http://mymenoplan.org/wp-content/uploads/2020/12/ms34.pdf)

[Buchanan DT, Landis CA, Hohensee C, Guthrie KA, Otte JL, Paudel M, Anderson GL, Caan B, Freeman EW, Joffe H, LaCroix AZ, Newton KM, Reed SD, Ensrud KE. Effects of yoga and aerobic exercise on actigraphic sleep parameters in menopausal women with hot flashes. J Clin Sleep Med 2016;13(1):11-18, 2017. [PMCID: PMC5181601]](http://mymenoplan.org/wp-content/uploads/2020/12/ms35.pdf)

[Oakley AE, Steiner RA, Chavkin C, Clifton DK, Ferrara LK, Reed SD. K Agonists as a novel therapy for menopausal hot flashes. Menopause 2015;22(12):1328-1334. [PMCID: PMC4651855]](http://mymenoplan.org/wp-content/uploads/2020/12/ms36.pdf)

[Jones SW, Guthrie KA, LaCroix AZ, Sternfeld B, Landis CA, Reed SD, Dunn A, Caan B, Cohen LS, Hunt J, Newton KM. Is heart rate variability associated with frequency and bother of vasomotor symptoms among healthy peri-menopausal and post-menopausal women? Clin Auton Res 2016;26(1):7-13. [PMCID: PMC4742392]](http://mymenoplan.org/wp-content/uploads/2020/12/ms38.pdf)

[Jones SM, Guthrie KA, Reed SD, Landis CA, Sternfeld B, LaCroix AZ, Dunn A, Burr RL, Newton KM. A yoga & exercise randomized controlled trial for vasomotor symptoms: Effects on heart rate variability. Complement Ther Med 2016;6:66-71. [PMCID: PMC4893767]](http://mymenoplan.org/wp-content/uploads/2020/12/ms39.pdf)

[McCurry S, Guthrie KA, Morin DM, Woods NF, Landis CA, Ensrud KE, Larson JC, Joffe H, Cohen LS, Hunt JR, Newton KM, Otte JL, Reed SD, Sternfeld B, Tinker LF, LaCroix AZ. Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial. JAMA Intern Med 2016;176(7):913-920. [PMCID: PMC4935624]](http://mymenoplan.org/wp-content/uploads/2020/12/ms40.pdf)

[Guthrie KA, Larson JC, Ensrud KE, Anderson GL, Carpenter JS, Freeman EW, Joffe, H, LaCroix AZ, Manson JE, Morin CM, Newton KM, Otte J, Reed SD, McCurry S. Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and subjective sleep quality in women with hot flashes: A pooled analysis of individual participant data from 4 MsFLASH trials. Sleep 2018:41(1);zsx190. [PMCID: PMC6380606]](http://mymenoplan.org/wp-content/uploads/2020/12/ms41.pdf)

[Diem SJ, LaCroix AZ. Reed SD, Larson JC, Newton KM, Ensrud KE, Woods NF, Guthrie KA. Effects of pharmacologic and non-pharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials. In press, Menopause 2020.](http://mymenoplan.org/wp-content/uploads/2022/01/ms42.pdf)

[Carpenter JS, Bakoyannis G, Otte JL, Chen CX, Rand KL, Woods NF, Newton KM, Joffe H, Manson JE, Freeman EW, Guthrie KA. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales. Menopause 2017;24(8):877-885. [PMCID: PMC6002749]](http://mymenoplan.org/wp-content/uploads/2020/12/ms44.pdf)

[Mitchell CM, Srinivasan S, Plantinga A, Wu MC, Reed SD, Guthrie KA, LaCroix AZ, Fiedler T, Munch M, Liu C, Hoffman NG, Blair IA, Newton K, Freeman EW, Joffe H, Cohen L, Fredricks DN. Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. Menopause 2018;25(5):500-507. [PMCID: PMC5898977]](http://mymenoplan.org/wp-content/uploads/2020/12/ms46.pdf)

[Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, LaCroix AZ, Caan B, Guthrie KA. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med 2018;178(5):681-690. [PMCID: PMC5885275]](http://mymenoplan.org/wp-content/uploads/2020/12/ms47.pdf)

[Mitchell CM, Reed SD, Guthrie KA. Good clinical practice in diagnosis of vulvovaginal symptoms – Reply. JAMA Intern Med 2018;178(8):1136-1137.](http://mymenoplan.org/wp-content/uploads/2020/12/ms47_05.pdf)

[Diem SJ, Guthrie KA, Mitchell CM, Reed SD, Larson JC, Ensrud KE, LaCroix AZ. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause 2018;25(10):1086-1093. [PMCID: PMC6136971]](http://mymenoplan.org/wp-content/uploads/2020/12/ms48.pdf)

[Guthrie KA, Caan B, Diem S, Ensrud KE, Greaves SR, Larson JC, Newton KM, Reed SD, LaCroix AZ. Facebook advertising for recruitment of midlife women with bothersome vaginal symptoms: a pilot study. Clin Trials 2019; 16(5):476-480. [PMCID: PMC6742530]](http://mymenoplan.org/wp-content/uploads/2020/12/ms49.pdf)

[Mitchell CM, Guthrie KA, Larson J, Diem S, LaCroix AZ, Caan B, Shifren JL, Woods NF, Heiman JR, Lindau S, Reed SD. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women. Menopause 2019;26(8):816-822. [PMCID: PMC6663586]](http://mymenoplan.org/wp-content/uploads/2020/12/ms50.pdf)

[Gibson CJ, Huang AJ, Larson JC, Mitchell C, Diem S, LaCroix A, Newton K, Reed S, Guthrie KA. Patient-centered change in the day-to-day impact of postmenopausalmvaginal symptoms: results from a multicentered randomized trial. In press, Am J Obstet Gynecol, 2020.](http://mymenoplan.org/wp-content/uploads/2020/12/ms51.pdf)

[Hunter MM, Guthrie KA, Larson JC, Reed SD, Mitchell CM, Diem SJ, LaCroix AZ, Huang A. Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial. J Sex Med 2020;17(1):117-125. [PMCID: PMC6956841]](http://mymenoplan.org/wp-content/uploads/2020/12/ms56.pdf)

[Reed SD, LaCroix AZ, Anderson GL, Ensrud KE, Caan B, Carpenter JS, Cohen L, Diem S, Freeman E, Joffe H, Larson JC, McCurry SM, Mitchell CM, Newton KM, Sternfeld S, Guthrie KA. Lights on MsFLASH: a review of contributions. Menopause 2020;27(4):473-484.](http://mymenoplan.org/wp-content/uploads/2020/12/ms58.pdf)

[Carpenter J, Tisdale J, Chen CX, Kovacs R, Larson J, Guthrie K, Ensrud K, Newton K, LaCroix AZ. A MsFLASH investigation of self-reported menopausal palpitations distress. Submitted, J Womens’ Health, 2020.](http://mymenoplan.org/wp-content/uploads/2020/12/ms60.pdf)

* + **Results Reference**  
    Definition: Indicate if the reference provided reports on results from this clinical study. Select NO

**Links**  
Definition: A web site directly relevant to the protocol may be entered, if desired. Do not include sites whose primary goal is to advertise or sell commercial products or services. Links to educational, research, government, and other non-profit web pages are acceptable. All submitted links are subject to review by ClinicalTrials.gov.

* + **URL**  
    North American Menopause Society: <https://www.menopause.org/for-women>  
      
    National Institute on Aging: <https://www.nia.nih.gov/health/topics/menopause>  
      
    The Office on Women’s Health-Menopause: <https://www.womenshealth.gov/menopause>
  + **MyMenoplan.**org

**Description**  
Definition: Title or brief description of the linked page.  
Limit: 254 characters.

* + North American Menopause Society: Official website of the North American Menopause Society   
      
    National Institute on Aging: NIA Information on Menopause  
    The Office on Women’s Health-Menopause: US Department of Health and Human Services website information on menopause
  + **MyMenoplan.**org: Website designed distilling information from MsFlash studies

**Available IPD and Supporting Information**

 **A.1 Document Upload Information**

* For details on uploading study documents (study protocol, statistical analysis plan, and/or informed consent form), see the [Document Upload Information](https://prsinfo.clinicaltrials.gov/results_definitions.html#DocumentUpload) in the Results Data Element Definitions.

 **A.2 Responsible Party Contact Information** **\*§**

* (*Provided as part of User Information or Organization Information in a PRS Account*)  
    
  Definition: Administrative information to identify and enable communication with the responsible party by telephone, email, and regular mail or delivery service. Responsible Party Contact Information is for the individual who is the responsible party or of a designated employee of the organization that is the responsible party. (*Will not be made public - for administrative purposes only*.)

Note: "Responsible party" means with respect to a clinical study, the sponsor of the clinical study, as defined in 21 CFR 50.3; or the principal investigator of such clinical study if so designated by a sponsor, grantee, contractor, or awardee, so long as the principal investigator is responsible for conducting the study, has access to and control over the data from the clinical study, has the right to publish the results of the study, and has the ability to meet all of the requirements for the submission of clinical study information. For a pediatric postmarket surveillance of a device product that is not a clinical trial, the responsible party is the entity who FDA orders to conduct the pediatric postmarket surveillance of the device product.

* + Name of Individual **\* Andrea Z. LaCroix**
* **Investigator Official Title**: Professor and Chief of Epidemiology, Family Medicine and Public Health
  + Physical Address **\***
* Name of Organizational Affiliation **\*** University of California San Diego
  + - Street Address **\* 9500 Gilman Drive**
    - City **\* La Jolla,**
    - State/Province **\*CA**
    - ZIP/Postal Code **\* 92093**
    - Country **\* USA**
    - Phone: **\*** 858-82**2-0627**
    - Ext: phone extension, if needed
    - Email: **\*** lacroix@ucsd.edu

 **History of Changes**

* January 18, 2017:  Document updated with data element changes per the FDAAA 801 final rule (42 CFR Part 11).
* February 07, 2017:  Formatting and typographical errors were corrected.
* April 18, 2017:  Added clarification that "(clinical trial)" has the same meaning as "Interventional" in Study Type and added definitions for "Yes" and "No" in U.S. Food and Drug Administration IND or IDE. Product Manufactured in and Exported from the U.S. and Outcome Measure Description definitions modified to describe when the information is required. Modified Cross-Reference element to address observational studies. Minor formatting changes.
* June 29, 2017:  Updated data elements related to Plan to Share IPD and moved to IPD Sharing Statement module. Added Document Upload Information reference (to Results Data Elements Definitions) as Appendix 1 (A.1.). Labeled Responsible Party Contact Information as Appendix 2 (A.2.). Brief Title, Study Phase - Early Phase 1, Collaborators, and Primary Purpose - Device Feasibility definitions updated with additional information to clarify meaning.
* June 27, 2018:   Typographical errors were corrected.
* March 7, 2019:   Updated Patient Registry definition to link to the most recent edition of the Registries for Evaluating Patient Outcomes: A User's Guide.
* October 1, 2020:   Increased field lengths.